PUBLISHER: FirstWord Group | PRODUCT CODE: 1473277
PUBLISHER: FirstWord Group | PRODUCT CODE: 1473277
Myelofibrosis - KOL insight
Explore the evolving landscape of myelofibrosis treatments in our latest insights report. Jakafi/Jakavi's relevance is poised to grow with new combination therapies, potentially increasing prescriptions and broadening patient treatment options. The recent approval of Ojjaara/Omjjara introduces a promising option for anaemic patients post-Jakafi, expected to see significant uptake based on MOMENTUM trial results. Additionally, Pelabresib is emerging as a groundbreaking non-JAK inhibitor in combination with Jakafi/Jakavi, heralding a new frontline treatment approach following the MANIFEST-2 trial. Stay ahead with these critical developments shaping the future of myelofibrosis care.
Table of Contents
Executive summary (9)
Treatment algorithm
Research objectives (5)
JAK inhibitors (32)
- Marketed therapies (32)
- Jakafi/Jakavi (ruxolitinib; Incyte/Novartis) (6)
- Vonjo/Epjevy/Enpaxiq (pacritinib; CTI BioPharma) (9)
- Inrebic (fedratinib; Bristol Myers Squibb) (6)
- Ojjaara/Omjjara (momelotinib; GSK) (11)
Exportin-1 protein inhibitors (9)
- Pipeline therapies (9)
- Xpovio (selinexor; Karyopharm Therapeutics) (9)
Proto-oncogene protein c-Bcl-2 inhibitors (10)
- Navitoclax (AbbVie) (10)
- Key insights summary (10)
TGF-Beta superfamily protein inhibitors (8)
- Reblozyl (luspatercept; Bristol Myers Squibb) (8)
- Key insights summary (8)
MDM2 inhibitors (9)
- Navtemadlin (Kartos Therapeutics) (9)
- Key insights summary (9)
Bromodomain and extra-terminal domain protein inhibitors (7)
- Pelabresib (MorphoSys/Novartis) (7)
- Key insights summary (7)
Telomerase inhibitors (8)
- Imetelstat (Geron Corporation) (8)
- Key insights summary (8)
Lysine-specific demethylase 1 (LSD1) inhibitors (9)
- Bomedemstat (Imago BioSciences/Merck & Co.) (9)
- Key insights summary (9)
Erythropoiesis stimulants (6)
- KER 050 (Keros Therapeutics) (6)
- Key insights summary (6)
Lysyl oxidase-like 2 (LOXL2) inhibitors (6)
- GB 2064 (Galecto) (6)
- Key insights summary (6)
Future treatment paradigm (7)
- Key insights summary (7)
Appendix (3)
- KOL details (3)
- KOLs from North America (1)
- KOLs from Europe (1)
